Determinants of lipid lowering therapy intensification in very high risk patients with dyslipidaemia eligible for PCSK9 monoclonal antibodies: 1-year outcomes of the PERI-DYS study
Despite eligibility for PCSK9-mAb treatment and management by specialised physicians, most patients did not reach the LDL-C target, and LLT intensification was rare. This suggests an underutilisation of available treatments, highlighting a gap in the management of high CV risk patients.
Authors
- Volker Schettler (ORCID: https://orcid.org/0000-0002-6193-6377)
- Andreas L. Birkenfeld (ORCID: https://orcid.org/0000-0003-1407-9023)
- Carsten Siegert
- Klaus G. Parhofer (ORCID: https://orcid.org/0000-0001-9873-0412)
- Elisabeth Steinhagen‐Thiessen (ORCID: https://orcid.org/0000-0003-3056-3317)
- David Pittrow (ORCID: https://orcid.org/0000-0003-1136-2616)
- Jens Klotsche (ORCID: https://orcid.org/0000-0002-2954-5755)
- Stefan Dexl
- Uwe Fraass (ORCID: https://orcid.org/0000-0001-6588-0318)
- Ulrich Laufs (ORCID: https://orcid.org/0000-0003-2620-9323)
- Bernd Hohenstein (ORCID: https://orcid.org/0000-0002-7306-3825)
Institutions
- Universitätsklinikum Tübingen (DE)
- German Rheumatism Research Centre (DE)
- Nephrologisches Zentrum Villingen-Schwenningen (DE)
- Amgen (Germany) (DE)
- University Hospital Leipzig (DE)
- GWT-TUD (Germany) (DE)
- Klinik und Poliklinik für Neurologie (DE)
- Nephrologisches Zentrum Emsland (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Acta cardiologica. Supplementum
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1080/00015385.2025.2490381
- Citations
- 2
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 4.01